shares in yourgene health plc dropped thursday after the company said that total revenue on a statutory basis for the first half of fiscal 2023 fell significantly as it transitions away from covid19related services postpandemic shares at 0906 gmt were down 05 pence or 13 at 325 pence the uk moleculardiagnostics specialist said that total revenue for the six months ended sept 30 fell to 96 million pounds 109 million from gbp175 million for the same period a year earlier excluding coronavirusrelated activities core revenue rose to gbp8 million from gbp7 million firsthalf total revenue represents more than 40 of consensus market expectations for the full year consistent with the historical revenue pattern the company said yourgene said it has been experiencing some erosion to margins which will only partially be offset by existing measures as it copes with inflationary and economic pressures and currency fluctuations it has prioritized expanding market shares in its core markets over nearterm margin protection and therefore expects margins to remain below the 60 level previously forecast for the remainder of fiscal 2023 it said the company said it continues to assess its cost base and is confident it can further reduce costs to achieve positive adjusted earnings before interest taxes depreciation and amortization in fiscal 2024